Anyone interested in Akero Therapeutics, Inc. (NASDAQ:AKRO) should probably be aware that the President, Andrew Cheng, recently divested US$423k worth of shares in the company, at an average price of US$53.99 each. On the bright side, that sale was only 2.0% of their holding, so we doubt it’s very meaningful, on its own.
Akero Therapeutics Insider Transactions Over The Last Year
In fact, the recent sale by Andrew Cheng was the biggest sale of Akero Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that even when the share price was below the current price of US$55.62, an insider wanted to cash in some shares. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can’t be sure if it does mean insiders think the shares are fully valued, so it’s only a weak sign. This single sale was just 2.0% of Andrew Cheng’s stake.
Insiders in Akero Therapeutics didn’t buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
See our latest analysis for Akero Therapeutics
NasdaqGS:AKRO Insider Trading Volume June 15th 2025
I will like Akero Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
Does Akero Therapeutics Boast High Insider Ownership?
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It appears that Akero Therapeutics insiders own 1.3% of the company, worth about US$58m. We’ve certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Does This Data Suggest About Akero Therapeutics Insiders?
Insiders haven’t bought Akero Therapeutics stock in the last three months, but there was some selling. And there weren’t any purchases to give us comfort, over the last year. Insider ownership isn’t particularly high, so this analysis makes us cautious about the company. We’re in no rush to buy! In addition to knowing about insider transactions going on, it’s beneficial to identify the risks facing Akero Therapeutics. Our analysis shows 5 warning signs for Akero Therapeutics (2 don’t sit too well with us!) and we strongly recommend you look at them before investing.
Of course Akero Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.